Activation of mitofusin 2 (Mfn2) by genetic or pharmacological tools restrained the mitochondrial fission and reduced ROS concentration, subsequently suppressing ovarian cancer progression [36]. This evidence concerns the gene MFN2 and ovarian cancer.